The m6A methyltransferase METTL16 negatively regulates MCP1 expression in mesenchymal stem cells during monocyte recruitment

Mesenchymal stem cells (MSCs) possess strong immunoregulatory functions, one aspect of which is recruiting monocytes from peripheral vessels to local tissue by secreting monocyte chemoattractant protein 1 (MCP1). However, the regulatory mechanisms of MCP1 secretion in MSCs are still unclear. Recently, the N6-methyladenosine (m6A) modification was reported to be involved in the functional regulation of MSCs. In this study, we demonstrated that methyltransferase-like 16 (METTL16) negatively regulated MCP1 expression in MSCs through the m6A modification. Specifically, the expression of METTL16 in MSCs decreased gradually and was negatively correlated with the expression of MCP1 after coculture with monocytes. Knocking down METTL16 markedly enhanced MCP1 expression and the ability to recruit monocytes. Mechanistically, knocking down METTL16 decreased MCP1 mRNA degradation, which was mediated by the m6A reader YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2). We further revealed that YTHDF2 specifically recognized m6A sites on MCP1 mRNA in the CDS region and thus negatively regulated MCP1 expression. Moreover, an in vivo assay showed that MSCs transfected with METTL16 siRNA showed greater ability to recruit monocytes. These findings reveal a potential mechanism by which the m6A methylase METTL16 regulates MCP1 expression through YTHDF2-mediated mRNA degradation and suggest a potential strategy to manipulate MCP1 expression in MSCs.

[1]  Wei Liu,et al.  METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis , 2022, Nature Cell Biology.

[2]  S. Gaffen,et al.  The RNA-binding protein IMP2 drives a stromal-Th17 cell circuit in autoimmune neuroinflammation , 2021, JCI insight.

[3]  Zhipeng Dai,et al.  METTL14 benefits the mesenchymal stem cells in patients with steroid-associated osteonecrosis of the femoral head by regulating the m6A level of PTPN6 , 2021, Aging.

[4]  Wentao Wang,et al.  Polysome profiling followed by quantitative PCR for identifying potential micropeptide encoding long non-coding RNAs in suspension cell lines , 2021, STAR protocols.

[5]  Hong Jiang,et al.  TTP protects against acute liver failure by regulating CCL2 and CCL5 through m6A RNA methylation , 2021, JCI insight.

[6]  R. Harman,et al.  Mesenchymal stromal cell‐secreted CCL2 promotes antibacterial defense mechanisms through increased antimicrobial peptide expression in keratinocytes , 2021, Stem cells translational medicine.

[7]  Yanfeng Wu,et al.  TNF-α-mediated m6A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis , 2021, Nature Communications.

[8]  Wei Huang,et al.  N6-methyladenosine methyltransferases: functions, regulation, and clinical potential , 2021, Journal of Hematology & Oncology.

[9]  Yanju Wu,et al.  Potential roles of N6-methyladenosine (m6A) in immune cells , 2021, Journal of translational medicine.

[10]  Huiyong Shen,et al.  The N6-methyladenosine demethylase ALKBH5 negatively regulates the osteogenic differentiation of mesenchymal stem cells through PRMT6 , 2021, Cell Death & Disease.

[11]  V. Ravichandiran,et al.  MCP-1: Function, regulation, and involvement in disease , 2021, International Immunopharmacology.

[12]  Q. Lan,et al.  The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance , 2021, Cancer Research.

[13]  Yue Xu,et al.  m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer , 2021, Frontiers in Cell and Developmental Biology.

[14]  Chuan He,et al.  m6A RNA methylation: from mechanisms to therapeutic potential , 2021, The EMBO journal.

[15]  Xiangyi Zheng,et al.  YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer , 2020, Molecular cancer.

[16]  Yubin Xie,et al.  RMVar: an updated database of functional variants involved in RNA modifications , 2020, Nucleic Acids Res..

[17]  O. Kim,et al.  Enhancing the Therapeutic Potential of CCL2-Overexpressing Mesenchymal Stem Cells in Acute Stroke , 2020, International journal of molecular sciences.

[18]  K. Shah,et al.  Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential. , 2020, Trends in pharmacological sciences.

[19]  N. Chandra,et al.  Chemokine signaling mediated monocyte infiltration affects anxiety-like behavior following blast injury , 2020, Brain, Behavior, and Immunity.

[20]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[21]  D. Whelan,et al.  Mesenchymal stromal cell derived CCL2 is required for accelerated wound healing , 2020, Scientific Reports.

[22]  J. Galipeau,et al.  CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury , 2020, Cell reports.

[23]  Lanjuan Li,et al.  Mesenchymal stromal cells promote liver regeneration through regulation of immune cells , 2020, International journal of biological sciences.

[24]  Guowei Li,et al.  Regulatory Role of RNA N6-Methyladenosine Modification in Bone Biology and Osteoporosis , 2020, Frontiers in Endocrinology.

[25]  Gang Yin,et al.  Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.

[26]  Gang Yin,et al.  Functions of N6-methyladenosine and its role in cancer , 2019, Molecular Cancer.

[27]  R. Krawetz,et al.  CCL2 But Not CCR2 Is Required for Spontaneous Articular Cartilage Regeneration Post‐Injury , 2019, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[28]  Megan Cully Chemical inhibitors make their RNA epigenetic mark , 2019, Nature Reviews Drug Discovery.

[29]  Liang Ming,et al.  The role of m6A RNA methylation in cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  Zhiyong Zhang,et al.  METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes , 2019, Autophagy.

[31]  Y. Wang,et al.  Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis , 2018, Nature Communications.

[32]  T. Mizuno,et al.  Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in Ldlr−/− mice , 2018, Cardiovascular research.

[33]  M. Pocard,et al.  CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer , 2018, Molecular Cancer.

[34]  E. Gelfand,et al.  Mesenchymal Stem Cells Recruit CCR2+ Monocytes To Suppress Allergic Airway Inflammation , 2018, The Journal of Immunology.

[35]  Chuan He,et al.  Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis , 2017, Cell Research.

[36]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[37]  Yang Xie,et al.  The U6 snRNA m6A Methyltransferase METTL16 Regulates SAM Synthetase Intron Retention , 2017, Cell.

[38]  Huiyong Shen,et al.  MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis , 2017, Journal of Molecular Medicine.

[39]  S. Bae,et al.  CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms , 2017, Scientific Reports.

[40]  J. Ringe,et al.  Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3‐Induced Myocarditis , 2017, Stem cells translational medicine.

[41]  W. Robinson,et al.  CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis , 2016, Annals of the rheumatic diseases.

[42]  M. Kupiec,et al.  Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq , 2012, Nature.

[43]  M. Gorospe,et al.  Chemokine Transcripts as Targets of the RNA-Binding Protein HuR in Human Airway Epithelium , 2011, The Journal of Immunology.

[44]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[45]  A. Poggi,et al.  Immunomodulatory Properties of Mesenchymal Stromal Cells: Still Unresolved "Yin and Yang". , 2019, Current stem cell research & therapy.

[46]  A. Shyu,et al.  Messenger RNA half-life measurements in mammalian cells. , 2008, Methods in enzymology.